Advice

following a full submission assessed under the end of life process:

tivozanib (Fotivda®) is accepted for restricted use within NHSScotland.

Indication under review: the first-line treatment of adult patients with advanced renal cell carcinoma and for adult patients who are vascular endothelial growth factor receptor and mammalian target of rapamycin pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced renal cell carcinoma (RCC).

SMC restriction: to first-line treatment of advanced RCC.

In a phase III, open-label, randomised, controlled study tivozanib increased progression free survival when compared with a multi-kinase inhibitor in patients with advanced RCC.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of tivozanib. This advice is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.

This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting

Download full details234KB (PDF)

Download

Medicine details

Medicine name:
tivozanib (Fotivda)
SMC ID:
1335/18
Indication:
For the first-line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are vascular endothelial growth factor receptor (VEGFR) and mammalian target of rapamycin (mTOR) pathway inhibitor-naive following disease progression after one prior treatment with cytokine therapy for advanced RCC.
Pharmaceutical company
EusaPharma
BNF chapter
Malignant disease and immunosuppression
Submission type
Full submission
Status
Restricted
Date advice published:
09 July 2018